|
101 |
Audit Readiness For Cell & Gene Therapy Companies
|
관리자 |
2025-02-03 |
1,076 |
|
100 |
From missing Analysis to Brand Protection Violations - FDA Warning Letter to Canadian Manufacturer
|
sureAssist |
2025-01-02 |
1,164 |
|
99 |
Risk Analysis in Case of Insufficient Process Validation
|
sureAssist |
2025-01-02 |
1,056 |
|
98 |
Microbiological monitoring: Adapting to new rapid methods regulatory demands
|
sureAssist |
2025-01-02 |
1,009 |
|
97 |
Count On Data Integrity Auditors Making These 10 Requests
|
sureAssist |
2025-01-02 |
960 |
|
96 |
What To Do When Your Regulatory Findings Need Quality Risk Management Action
|
sureAssist |
2024-12-26 |
967 |
|
95 |
The cleanroom debate: Epoxy flooring vs raised flooring
|
sureAssist |
2024-12-26 |
1,066 |
|
94 |
Inadequate Classification leads to Warning Letter
|
sureAssist |
2024-12-26 |
810 |
|
93 |
FDA criticises the Use of pharmaceutical Facilities for industrial Products
|
sureAssist |
2024-12-26 |
801 |
|
92 |
GMP Requirements for Ready to Sterilize (RTS) and Ready to Use (RTU) Containers
|
sureAssist |
2024-12-26 |
848 |
